Kenneth Bagley

Dr. Kenneth Bagley currently lead the genetic adjuvant discovery and development program at Profectus BioSciences (profectusbiosciences.com). I am developing four novel genetic adjuvants for human use. I am also intimately involved in the development of genetic vaccines targeting HSV-2, HIV, Influenza and HPV. I currently lead the development of the HSV-2 and universal influenza vaccine programs. Since starting at Profectus in 2006, I have been awarded four phase I SBIR grants and one phase II SBIR grant totaling over five million dollars.